Skip to main content
. 2012 May 16;10:93. doi: 10.1186/1479-5876-10-93

Figure 3.

Figure 3

FLJ10540 was up-regulated by osteopontin stimulation in human cancer cells. (A and B, left panel) The mRNA expression level of FLJ10540 was determined by Q-RT-PCR in TW01, and Hone1 cells with a dose-dependent manner of osteopontin. The results were normalized against the expression level of GAPDH mRNA in each osteopontin-treated cell. (A and B, right panel) The protein expression level of FLJ10540 was determined by Western blotting in TW01, and Hone1 cells. After treatment with various concentrations of osteopontin for 30 min, the total protein was extracted and the cell lysates (50 μg) of each treated cell were subjected to immunoblot analysis with anti-FLJ10540 and β-actin antibodies. β-actin was used as a control. Data are representative of three independent experiments done in triplicate. (C) Luciferase assays were done to detect promoter activity of FLJ10540 in transfected TW01 cells in the presence or absence of osteopontin. The luciferase activity in 1μg of cell lysate was normalized to β-galactosidase activity. Data are representative of three independent experiments done in triplicate.